<- Go Home
Codexis, Inc.
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Market Cap
$204.6M
Volume
620.2K
Cash and Equivalents
$18.3M
EBITDA
-$62.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$12.3M
Profit Margin
24.71%
52 Week High
$6.08
52 Week Low
$1.90
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
-2.53
Price / Tangible Book Value
N/A
Enterprise Value
$204.3M
Enterprise Value / EBITDA
-3.53
Operating Income
-$67.0M
Return on Equity
115.53%
Return on Assets
-30.06
Cash and Short Term Investments
$59.8M
Debt
$59.5M
Equity
$49.6M
Revenue
$49.8M
Unlevered FCF
-$28.7M
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium